| 陈雅茹,胡利梅,任卫东,许峥嵘,谷 君,史 丽.利拉鲁肽对二甲双胍控制不佳的肥胖/超重2型糖尿病患者氧化应激、NLRP3炎症小体及脂肪因子水平的影响[J].现代生物医学进展英文版,2023,(10):1940-1944. |
| 利拉鲁肽对二甲双胍控制不佳的肥胖/超重2型糖尿病患者氧化应激、NLRP3炎症小体及脂肪因子水平的影响 |
| Effects of Lilalutide on Oxidative Stress, NLRP3 Inflammasome and Adipokines Levels in Obese/Overweight Type 2 Diabetes Mellitus Patients with Poorly Controlled Metformin |
| Received:November 10, 2022 Revised:November 30, 2022 |
| DOI：10.13241/j.cnki.pmb.2023.10.026 |
| 中文关键词: 利拉鲁肽 二甲双胍 肥胖 超重 2型糖尿病 氧化应激 NLRP3炎症小体 脂肪因子 |
| 英文关键词: Liraglutide Metformin Obesity Overweight Type 2 diabetes mellitus Oxidative stress NLRP3 inflammasome Adipokines |
| 基金项目:河北省卫健委2019年度医学科学研究计划项目（20190879）；河北省财政厅2018年政府资助专科能力建设和专科带头人培养项目（361009） |
|
| Hits: 733 |
| Download times: 455 |
| 中文摘要: |
| 摘要 目的：探讨利拉鲁肽对二甲双胍控制不佳的肥胖/超重2型糖尿病（T2DM）患者氧化应激、NLRP3炎症小体及脂肪因子水平的影响。方法：选择2018年2月-2020年1月期间河北北方学院附属第一医院收治的二甲双胍控制不佳的肥胖/超重T2DM患者160例。按照随机数字表法将患者分为对照组（80例，阿卡波糖治疗）和研究组（80例，阿卡波糖联合利拉鲁肽治疗）。观察两组的收缩压（SBP）、腰臀比（WHR）、体质量指数（BMI）、胰岛素抵抗指标、糖脂代谢指标、氧化应激指标、核苷酸结合寡聚化结构域样受体蛋白3（NLRP3）炎症小体及脂肪因子水平变化情况。结果：两组治疗后BMI、WHR、SBP均下降，且研究组的下降幅度更大（P<0.05）。两组治疗后胰岛?茁细胞分泌功能指数（HOMA-?茁）升高，胰岛素抵抗指数（HOMA-IR）下降，且研究组的改变幅度更大（P<0.05）。两组治疗后甘油三酯（TG）、总胆固醇（TC）、糖化血红蛋白（HbA1c）、低密度脂蛋白胆固醇（LDL-C）、空腹血糖（FPG）下降，高密度脂蛋白胆固醇（HDL-C）升高，且研究组的改变幅度更大（P<0.05）。两组治疗后丙二醛（MDA）下降，谷胱甘肽过氧化物酶（GSH-PX）、超氧化物歧化酶（SOD）升高，且研究组的改变幅度更大（P<0.05）。两组治疗后NLRP3炎症小体均下降，且研究组的改变幅度更大（P<0.05）。两组治疗后脂联素升高，瘦素下降，且研究组的改变幅度更大（P<0.05）。结论：利拉鲁肽应用于治疗二甲双胍控制不佳的肥胖/超重T2DM患者，可减轻氧化应激，有效改善糖脂代谢，调节NLRP3炎症小体及脂肪因子水平。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the effect of of lilalutide on oxidative stress, NLRP3 inflammasome and adipokines levels in obese/overweight type 2 diabetes mellitus(T2DM) patients with poorly controlled metformin. Methods: 160 obese/overweight T2DM patients with poorly controlled metformin who were admitted to the First Affiliated Hospital of Hebei North University from February 2018 to January 2020 were selected. The patients were divided into the control group (80 cases, treated with acarbose) and the study group (80 cases, treated with acarbose combined with liraglutide) according to the method of random number table. The changes of systolic blood pressure (SBP), waist hip ratio (WHR), body mass index(BMI), insulin resistance indexes, glycolipid metabolism indexes, oxidative stress indexes, nod-like receptor protein 3 (NLRP3) inflammasome and adipokines levels were observed in the two groups. Results: After treatment, BMI, WHR and SBP in the two groups decreased, and the decrease range in the study group was greater(P<0.05). After treatment, the islet beta cell secretion function index (HOMA-β) in the two groups increased, and insulin resistance index(HOMA-IR) decreased, and the change range in the study group was greater (P<0.05). After treatment, triglycerides (TG), total cholesterol (TC), glycosylated hemoglobin (HbA1c), low-density lipoprotein cholesterol (LDL-C), and fasting blood glucose (FPG) in the two groups decreased, and high-density lipoprotein cholesterol (HDL-C) increased, and the change range in the study group was greater(P<0.05). After treatment, malondialdehyde (MDA) in the two groups decreased, glutathione peroxidase (GSH-PX) and superoxide dismutase(SOD) increased, and the change range in the study group was greater(P<0.05). After treatment, the NLRP3 inflammasome in the two groups decreased, and the change range in the study group was greater(P<0.05). Adiponectin increased in the two groups after treatment, and leptin decreased, and the change range in the study group was greater(P<0.05). Conclusion: Lilalutide is used to treat obese/overweight T2DM patients with poorly controlled metformin, which can reduce oxidative stress, effectively improve glucose and lipid metabolism, and regulate the NLRP3 inflammasome and adipokines levels. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
